Interested in learning on expert management of infections in a wide range of special populations? Do you need to boost your ideas on AB stewardship? The ID team in HospitalUVRocio welcomes ESCMID observership program! 📍Meet us at #ESCMIDGlobal2024 Fireplace today at 2:00pm!

Cefiderocol non-inferior and non-superior to SOC for healthcare-associated GN-BSI (also for carbapenem-resistant BSI). Limited data to clarify previous concerns about cefiderocol safety for CRAB. David Paterson on behalf of the GAME CHANGER Trial team at #ESCMIDGlobal2024 🔝

🆕 Metaanalysis of observational studies of short vs prolonged treatment for P. aeruginosa BSI (n=1746) ⏱️ No differences in a propensity score-weighted composite outcome of recurrence+mortality 💪🏼Hope to confirm this with SHORTEN-2 trial 📖journalofhospitalinfection.com/article/S0195-… Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟

SHORTEN-2 trial Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 Obligatory reading for any duration of therapy observational study sciencedirect.com/science/articl…

The optimal duration of therapy for Pseudomonas aeruginosa bloodstream infection is unknown, with prolonged therapy frequently favored due to severity of infection, patient complexity, risk of multi-drug resistance, and high mortality #IDXposts

We’re so proud of this team! 3️⃣5️⃣ Spanish hospitals have already joined the project, and we have just surpassed 60% of the trial sample. The SHORTEN-2 trial family keeps growing in our 2nd Annual Researchers’ Meeting at #XVIICongresoSEIMC 🤩 SEIMC GEIRAS (SEIMC) CIBERINFEC

Systematic review and meta-analysis of extended infusion vs conventional infusion

The largest study of Pseudomonas endocarditis to date 🆕️🔥#JAC Sunish Shah Ryan Shields Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis Combination therapy did not improve clinical outcomes #IDXposts #IEwiki academic.oup.com/jac/article-ab…

Recruitment has skyrocketed in the last weeks 🚀 The final countdown is on: 100 patients left to close the SHORTEN-2 trial! Outstanding commitment of the 38 participating centers across Spain #TeamPride 💪🏼

Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 Todd C. Lee Brad Spellberg Only 8️⃣0️⃣ patients to go! The SHORTEN-2 trial team has maintained a great recruitment pace throughout the summer. We expect to complete patient enrollment in the first half of 2025! 🤞🏻

MDR-P. aeruginosa are usually underrepresented in studies on treatment duration. This observational study on HAP/VAP by MDR-PA did not find improved outcomes for treatments >8d. 📚 bmcinfectdis.biomedcentral.com/articles/10.11… Hope to confirm this in SHORTEN-2 trial! ICYMI Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 #ShorterIsBetter

SHORTEN-2 trial Thanks for sharing Small study Can't wait for the results of SHORTEN-2 trial

🧬🔬 Personal investigador de @CIBERINFEC, IdISBa y HU Son Espases han desarrollado una herramienta genómica que detecta la resistencia en P. aeruginosa sin necesidad de cultivo previo. 🔗Noticia completa: ciberisciii.es/noticias/desar…

~ 5 % (170/ 3608 ) , Pseudomonas spp , sub group analysis? We have more data about Pseudomonas bactremia, awaiting for SHORTEN-2 trial #idxposts #IDWeek2024

Los nuevos β-lactámicos permiten tratar Pseudomonas que antes no tenían tratamiento, pero…¿son mejores que los anteriores? Este metaanálisis de ECA muestra que no son superiores a las opciones de siempre si están disponibles: ajicjournal.org/article/S0196-… 👐🏻 Cuídalos, haz que duren

A brilliant thread on the state of the art of treatment duration for P. aeruginosa infections in immunocompromised hosts from #IDWeek2024 With 1 in 3 patients in SHORTEN-2 trial expected to be immunocompromised, we hope to contribute with additional data on this topic soon!🤞🏻

~ 5 % (170/ 3608 ) Pseudomonas spp , sub group analysis? Now we have more data about Pseudomonas bactremia, awaiting for the definitive answer from SHORTEN-2 trial SHORTEN-2 : RCT 7 vs 14 days of treatment for P. aeruginosa BSI. Brad Spellberg Todd C. Lee #idxposts Systematic Rev*

aecirujanos AEU RAEU - Spanish Urology Residents Working Group @Uro-NefroHUVR CirugíaGeneralHUVR SEDAR SEMICYUC Varios estudios sugieren que las infecciones no complicadas del injerto podrían tratarse 7 días. Aun así, los pacientes trasplantados han sido excluidos de la mayoría de ensayos de duración. ¡Hora de sumarlos al movimiento #ShorterIsBetter! 😉 🔓sciencedirect.com/science/articl… 🧵(3/6)